Resistance to cosmetic botulinum toxin A: A 15-patient case series across 12 sites
- PMID: 39553483
- PMCID: PMC11564985
- DOI: 10.1016/j.jdin.2024.08.021
Resistance to cosmetic botulinum toxin A: A 15-patient case series across 12 sites
Keywords: botox; botulinum toxin A; botulinum toxin B; cosmetic dermatology; neuromodulator; neurotoxin; rhytids; wrinkles.
Conflict of interest statement
Dr C. G. Wambier has served a consultant for Allergan Aesthetics, AbbVie Company and as a speaker of Galderma Laboratories and cosmetic dermatologic surgery editor of the Surgical & Cosmetic Dermatology Journal and Brazilian Society of Dermatology (SBD). Dr Bertucci has served as a speaker, consultant, and/or investigator for Allergan Aesthetics, AbbVie Company, Clarion Medical Technologies, Cutera, Evolus, Galderma, L’Oreal, Revance, and Teoxane. Dr Carruthers has served as consultant for Acorn, Alastin, Appiell, Allergan Aesthetics, AbbVie Company, Avari, Bonti (now with Allergan/AbbVie), Del Nova, Evolus, Fount Bio, In Mode, Inverse Genomic Ltd, Jeune Aesthetics, Merz, Revance Biopharma, Object Pharma, Sofwave, is an author and editor for Elsevier, is an author for “Up to Date” Neuromodulators and Fillers, is an assistant editor for Dermatologic Surgery, is a reviewer for the Aesthetic Surgery Journal, Ophthalmic Plastic and Reconstructive Surgery, and Plastic and Reconstructive Surgery. Dr Kaufman has been an investigator for Allergan Aesthetics, AbbVie Company, Croma, Galderma, MedyTox, Merz, and Revance. Dr Guadanhim is speaker and investigator for Allergan Aesthetics and AbbVie Company. Dr Hexsel is a consultant for Galderma Laboratories, and cosmetic dermatology editor of the Surgical & Cosmetic Dermatology Journal and Brazilian Society of Dermatology (SBD). Drs Mirza, S. P. F. Wambier, Martin, Sterling, Brasileiro, Marçon, Brown, and Rosenberg have no conflicts of interest to declare.
References
LinkOut - more resources
Full Text Sources